Insulin Aspart
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Insulin aspart is an FDA-approved rapid-acting insulin peptide/protein hormone analog used for mealtime and correction glycemic control in diabetes. This app supports FDA-approved prescription insulin aspart products only, such as NovoLog and Fiasp when selected by the prescriber; non-prescribed, compounded, research-use, or product-substitution use is unsupported.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Insulin aspart is an FDA-approved rapid-acting insulin peptide/protein hormone analog used for mealtime and correction glycemic control in diabetes. NutriStack rates the supporting evidence as strong. Common adult dosing is Individualized prescription dosing only; meal dose, correction dose, pump settings, and product switching must be set by the diabetes prescriber using glucose monitoring and clinical context., though a prescriber sets the actual dose. This profile indexes 14 sources.
The bottom line
Evidence rating strong. Most-documented uses: rapid onset (15–20 minutes) for mealtime coverage, improved postprandial glucose control vs regular insulin, shorter duration reduces late hypoglycemia. 14 sources indexed (1998–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
A recombinant insulin analogue where proline at position B28 is replaced by aspartic acid, reducing hexamer formation and accelerating subcutaneous absorption. Once in the bloodstream, it binds insulin receptors and activates the same intracellular signaling cascade as endogenous insulin, promoting glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and glycogenolysis.4,1
Dosing & protocol.
NovoLog is administered immediately before a meal as prescribed; Fiasp is administered at the start of a meal or within 20 minutes after starting. Rotate sites, verify product/device, and maintain a backup plan for pump failure.
Full safety detail.
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
3- 1Effectiveness of Faster Aspart versus Insulin Aspart in Children with Type 1 Diabetes: A Meta-AnalysisSource linkedPMIDWei J, Wang Y · Iranian journal of public health · 2024
Wei J, Wang Y. Effectiveness of Faster Aspart versus Insulin Aspart in Children with Type 1 Diabetes: A Meta-Analysis. Iranian journal of public health. 2024
- 2Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-AnalysisSource linkedPMIDEdina BC, Tandaju JR, Wiyono L · Cureus · 2022
Edina BC, Tandaju JR, Wiyono L. Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis. Cureus. 2022
- 3Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetesSource linkedPMIDValentine WJ, Pollock RF, Plun-Favreau J et al. · Current medical research and opinion · 2010
Valentine WJ, Pollock RF, Plun-Favreau J et al.. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current medical research and opinion. 2010
Randomized controlled trials
3- 4Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid(®) (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 studySource linkedPMIDDongre SA, Kulkarni GA, Mishra A et al. · Research in pharmaceutical sciences · 2024
Dongre SA, Kulkarni GA, Mishra A et al.. Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid(®) (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study. Research in pharmaceutical sciences. 2024
- 5Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trialSource linkedPMIDYao J, Guo X, Sun L et al. · Current medical research and opinion · 2022
Yao J, Guo X, Sun L et al.. Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial. Current medical research and opinion. 2022
- 6A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetesSource linkedPMIDGoldberg RB Einhorn D Lucas CP et al. · Diabetes Care · 1998
Reference material
8- 7NOVOLOG (insulin aspart) injection, solution: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
Label includes hypoglycemia and hypersensitivity contraindications plus warnings for pen sharing, regimen changes, medication errors, pump malfunction, hypoglycemia, hypokalemia, hypersensitivity, TZD-related heart failure, and pregnancy risk language.
- 8FIASP (insulin aspart) injection, solution: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
Label covers Fiasp administration at the start of a meal or within 20 minutes after starting, no mixing with other insulin, pump malfunction, pen/cartridge sharing, hypoglycemia, hypokalemia, hypersensitivity, and pregnancy risk language.
- 9FDA Insulin safety informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
FDA advises not sharing insulin needles, pens, or cartridges and emphasizes using the correct insulin type and device.
- 10Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-805.Source linkedPMID
- 11Russell-Jones D et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40(7):943-950.Source linkedPMID
- 12Rakab MS et al. Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: a systematic review and meta-analysis of randomized control trials. Front Endocrinol (Lausanne). 2025.Source linkedPMID
- 13Kellerer M, Kaltoft MS, Lawson J et al.. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. Diabetes, obesity & metabolism. 2022Source linkedPMID
- 14Karonova TL, Mayorov AY, Magruk MA et al.. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid(®) Penfill(®)) in Type 1 diabetes mellitus. Journal of comparative effectiveness research. 2021Source linkedPMID
Common questions.
Quick answers about Insulin Aspart, drawn from the data on this page.
What is Insulin Aspart?
Insulin aspart is an FDA-approved rapid-acting insulin peptide/protein hormone analog used for mealtime and correction glycemic control in diabetes. This app supports FDA-approved prescription insulin aspart products only, such as NovoLog and Fiasp when selected by the prescriber; non-prescribed, compounded, research-use, or product-substitution use is unsupported.
What is Insulin Aspart used for?
Commonly cited benefits of Insulin Aspart include: Rapid onset (15–20 minutes) for mealtime coverage; Improved postprandial glucose control vs regular insulin; Shorter duration reduces late hypoglycemia; Compatible with insulin pump therapy; Fiasp formulation offers even faster onset. NutriStack rates the overall evidence as strong.
What is a typical dose of Insulin Aspart?
A typical adult dose of Insulin Aspart is Individualized prescription dosing only; meal dose, correction dose, pump settings, and product switching must be set by the diabetes prescriber using glucose monitoring and clinical context.. The commonly recommended form is FDA-approved prescription rapid-acting insulin aspart product selected by the prescriber. Do not substitute products, pens, vials, cartridges, PumpCart, or pump use without prescriber/pharmacist direction.. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Insulin Aspart?
Reported side effects include hypoglycemia, weight gain, injection site reactions, lipodystrophy, hypokalemia, allergic reactions (rare). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Insulin Aspart?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Insulin Aspart in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.